Andere talen Cyclo Therapeutics, Inc.

Aandelen

CYTH

US23254X2018

Vertraagde tijd Nasdaq Andere beurzen 17:12:13 20-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,37 ^USD	-2,14%		-2,14%	-13,84%

01/05	CYCLO THERAPEUTICS, INC. : HC Wainwright bevestigt koopadvies	ZM
18/03	Cyclo Therapeutics, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	16/05
Cyclo Therapeutics : Corporate Presentation	02/05
Cyclo Therapeutics : Corporate Presentation	18/04
Cyclo Therapeutics : Corporate Presentation	18/03
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	18/03
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimer's Disease	15/03
Cyclo Therapeutics Granted Patent Covering Use of Trappsol Cyclo for Alzheimer's Disease	14/03
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease	14/03
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office	30/01
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office	29/01
Cyclo Therapeutics : Modification to Rights of Security Holders - Form 8-K	28/12
Cyclo Therapeutics, Applied Molecular Transport Complete Merger	27/12
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.	27/12
Cyclo Therapeutics, Inc. Appoints Shawn Cross to the Board of Directors	27/12
Cyclo Therapeutics, Inc. completed the acquisition of Applied Molecular Transport Inc. from a group of shareholders for $10.2 million.	27/12
Cyclo Therapeutics : Scientific Presentation	20/12
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1	18/12
Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1	18/12
Cyclo Therapeutics : Material Event - Form 8-K	18/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cyclo Therapeutics, Inc.

Aandelen

CYTH

US23254X2018

Andere talen

Filters